VC-backed Bolt Biotherapeutics debuts IPO

Bolt Biotherapeutics Inc has gone public after pricing its 11.5 million shares at $20 per share.

Bolt Biotherapeutics Inc has gone public after pricing its 11.5 million shares at $20 per share. The stock began trading February 5, 2021 on the NASDAQ under the ticker symbol “BOLT.” Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities are the lead underwriters. Bolt Biotherapeutics’ pre-IPO backers include Novo Holdings, Vivo Capital, Sofinnova Ventures, RA Capital, Pivotal BioVenture and Rock Springs Capital.

PRESS RELEASE

REDWOOD CITY, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the pricing of its upsized initial public offering of 11,500,000 shares of common stock at a price to the public of $20.00 per share. In addition, Bolt has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of common stock solely to cover over-allotments, if any, at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market under the symbol “BOLT” on February 5, 2021.

Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities are acting as joint bookrunners for the offering.

The offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525, ext. 6105 or by email at syndicate@svbleerink.com.

Registration statements relating to these securities have been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.